Both hand cooling and compression were effective in preventing sensory chemotherapy-induced peripheral neuropathy during taxane-based chemotherapy. https://ja.ma/3DINTnV
JAMA Oncology
图书期刊出版业
Chicago，Illinois 38,006 位关注者
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
关于我们
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- 网站
-
https://jamanetwork.com/journals/jamaoncology
JAMA Oncology的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 5,001-10,000 人
- 总部
- Chicago，Illinois
- 创立
- 2015
- 领域
- Oncology
动态
-
Chimeric antigen receptor–T-cell (CAR-T) therapy has revolutionized the treatment of hematologic cancers, but there is growing concern about the risk of second primary cancers (SPCs) following therapy. This review discusses the pathobiology, epidemiology, and mitigation strategies for SPCs. https://ja.ma/4bJuDDe
-
-
In prostate cancer patients on active surveillance, high polygenic risk score was associated with risk of upgrading as well as higher prostate-specific antigen density and tumor multifocality. https://ja.ma/4kyth2d
-
-
Cancer prevention and screening activities were the main contributors to reductions in mortality due to the most common cancers in the US over the past 45 years. https://ja.ma/3DGjC9b
-
-
Viewpoint: Despite the effectiveness of CAR-T therapy for various blood cancers, its adoption is limited in the US due to infrastructure challenges and restrictive insurance policies. https://ja.ma/4iqTG0b
-
-
Most viewed in the last 7 days from JAMA Oncology: Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. https://ja.ma/41M4vEo
-
-
Both hand cooling and compression were effective in preventing sensory chemotherapy-induced peripheral neuropathy during taxane-based chemotherapy. https://ja.ma/4kuVIy3
-
-
Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head and neck cancer demonstrated favorable survival and less toxic effects among responders receiving response-adapted chemoradiation. https://ja.ma/4h6MAwM
-
-
A modified classification of progressive disease based on PD patterns in patients treated with immune checkpoint inhibitors showed an association with postprogression survival (PPOS) across various solid tumor. https://ja.ma/41swCHD
-
-
Men with clinically suspected prostate cancer and negative MRI results can safely avoid biopsies with appropriate monitoring, validating the high negative predictive value of prebiopsy MRI in community healthcare settings. https://ja.ma/41Ip1pL
-